Your doctor may adjust your dosing regimen based on your bleeding pattern and physical activity.
APPROVED
FOR ONCE-WEEKLY
PROPHYLAXIS
To prevent or reduce the number of bleeding episodes in people with hemophilia B
Be ready for the unexpected
Once-weekly Rebinyn® helps you keep Factor 9 levels higher for longer.a

APPROVED
FOR ONCE-WEEKLY
PROPHYLAXIS
To prevent or reduce the number of bleeding episodes in people with hemophilia B
BE READY FOR THE
UNEXPECTED
Once-weekly Rebinyn® helps
you keep Factor 9 levels higher for longer.a

aRebinyn® achieved and maintained higher factor levels than recombinant Factor 9 based upon a phase 1 study comparing 25, 50, and 100 IU/kg single doses of Rebinyn® to a 50 IU/kg single dose of standard half-life recombinant Factor 9 in 7 adults and a 50 IU/kg dose of plasma-derived Factor 9 in 8 adults. For Rebinyn®, estimated average Factor 9 activity is adjusted to a dose of 50 IU/kg. Incremental recovery at 30 minutes (IR30) and half-life were higher and longer with Rebinyn® than recombinant Factor 9 (IR30 0.0131 vs 0.0068 (IU/mL)/(IU/kg) and half-life 93 vs 19 hours). The clinical relevance of these pharmacokinetic differences is unknown. Incremental recovery is the increase in plasma concentration per IU/kg of factor administered. Half-life is the time it takes for the level of factor in the blood to fall by half (50%).
SIMPLE ONCE-WEEKLY DOSING FOR ROUTINE PROPHYLAXIS:
SIMPLE ONCE-WEEKLY DOSING FOR ROUTINE PROPHYLAXIS:
MAINTAINING FACTOR LEVELS BETWEEN DOSES

The World Federation of Hemophilia (WFH)b says an extended half-life prophylaxis can allow individuals to keep Factor 9 levels in the non-hemophilia range (greater than 40%) for a significant amount of time.
The World Federation of Hemophilia (WFH)b says an extended half-life prophylaxis can allow individuals to keep Factor 9 levels in the non-hemophilia range (greater than 40%) for a significant amount of time.
The World Federation of Hemophilia (WFH)b says an extended half-life prophylaxis can allow individuals to keep Factor 9 levels in the non-hemophilia range (greater than 40%) for a significant amount of time.
The World Federation of Hemophilia (WFH)b says an extended half-life prophylaxis can allow individuals to keep Factor 9 levels in the non-hemophilia range (greater than 40%) for a significant amount of time.
bWFH offers guidelines that inform shared decision-making between patients, caregivers, and healthcare providers based on data from existing peer-reviewed findings.
REBINYN® HELPS YOU ACHIEVE HIGH FACTOR LEVELS SO YOU
CAN BE READY FOR THE UNEXPECTEDc

Previously treated adults achieved Factor 9 levels in the non-hemophilia range (greater than 40%)c




cData represent mean steady-state pharmacokinetic profiles from previously treated adolescent/adult patients with moderate to severe hemophilia B (n=9) taking repeated doses of Rebinyn® 40 IU/kg once weekly. Factor 9 levels were within the non-hemophilia range (greater than 40%) for 5.4 days (approximately 80% of the week).
dBased on the mean steady-state post-dose peak levels and pre-dose trough levels 168 hours after administered Rebinyn® 40 IU/kg once weekly in previously treated patients (20 adult and 9 adolescent patients).
eHalf-life: Time required for Factor 9 to decline to half its value.
fBased on analysis using a 1-stage assay in patients (n=6) aged 18 and older, the half-life at steady state was 115 hours following once-weekly (40 IU/kg) dosing; in patients (n=3) aged 13 to 17, the half-life at steady state was 103 hours. Following single-dose administration (40 IU/kg) in the same patient population, the half-life was 83 hours (adults) and 89 hours (adolescents).
ESTABLISHED SAFETY PROFILE
ESTABLISHED SAFETY PROFILE
Clinical trials over
13 YEARS
showed 0 inhibitors and 0 blood clots in previously treated patients.
The formation of inhibitors (neutralizing antibodies) to Factor 9 has occurred following Rebinyn®. Common adverse reactions (incidence ≥1%) in PUPs reported in clinical trials for Rebinyn® included Factor 9 inhibitors. The use of Factor 9-containing products has been associated with blood clots.

WE'RE HERE TO HELP
Wondering about Rebinyn® or living with hemophilia B? Our Hemophilia Community Liaisons (HCLs) are here to answer your questions and connect you with the resources you need.

WE'RE HERE TO HELP
Wondering about Rebinyn® or living with hemophilia B? Our Hemophilia Community Liaisons (HCLs) are here to answer your questions and connect you with the resources you need.